Literature DB >> 10954763

Treatment of type II gastric carcinoid tumors with somatostatin analogues.

P Tomassetti1, M Migliori, G C Caletti, P Fusaroli, R Corinaldesi, L Gullo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10954763     DOI： 10.1056/NEJM200008243430805

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  32 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  Gastric carcinoids: between underestimation and overtreatment.

Authors:  Sara Massironi; Valentina Sciola; Matilde-Pia Spampatti; Maddalena Peracchi; Dario Conte
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

Review 3.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

4.  [Neuroendocrine neoplasia of the stomach : What is new?]

Authors:  T Knösel; C Reiter; G Schubert-Fritschle; A Altendorf-Hofmann; T Kirchner
Journal:  Pathologe       Date:  2017-03       Impact factor: 1.011

5.  Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).

Authors:  Sylvain Manfredi; Thomas Walter; Eric Baudin; Romain Coriat; Philippe Ruszniewski; Thierry Lecomte; Anne-Pascale Laurenty; Bernard Goichot; Vincent Rohmer; Guillaume Roquin; Oana-Zvetlana Cojocarasu; Catherine Lombard-Bohas; Côme Lepage; Jeff Morcet; Guillaume Cadiot
Journal:  Endocrine       Date:  2017-06-29       Impact factor: 3.633

Review 6.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

Authors:  Ting-Ting Li; Feng Qiu; Zhi Rong Qian; Jun Wan; Xiao-Kun Qi; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 7.  Advances in the treatment of neuroendocrine tumors.

Authors:  Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2005-09

8.  Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas.

Authors:  Melanie L Richards; Paul Gauger; Norman W Thompson; Thomas J Giordano
Journal:  World J Surg       Date:  2004-06-16       Impact factor: 3.352

Review 9.  Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.

Authors:  Paola Tomassetti; Teresa Salomone; Marina Migliori; Davide Campana; Roberto Corinaldesi
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.